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Abstract
In the last two decades there have been dramatic changes in the epidemiology of Clostridium difficile infection
(CDI), with increases in incidence and severity of disease in many countries worldwide. The incidence of CDI has
also increased in surgical patients. Optimization of management of C difficile, has therefore become increasingly
urgent. An international multidisciplinary panel of experts prepared evidenced-based World Society of Emergency
Surgery (WSES) guidelines for management of CDI in surgical patients.
Executive summary
In the last two decades, the dramatic increase in inci-
dence and severity of Clostridium difficile infection
(CDI) in many countries worldwide [1], has made CDI a
global public health challenge [2–5]. Recently two com-
prehensive sets of guidelines for management of CDI
were published [6, 7] that do not address issues specific-
ally with regard to surgeons. CDI in surgical patients is
of particular interest. Surgery, especially gastrointestinal
surgery, may predispose patients to the development of
CDI. Surgery is also a treatment option in severe cases
of CDI [8–11]. Optimization of the perioperative CDI pa-
tient management is therefore necessary for reduction in
health care costs, as well as patient morbidity and mortal-
ity. To provide empirical guidelines for the surgeon called
upon to assist in the care of the CDI patient, an inter-
national multidisciplinary panel of experts worldwide have
prepared these evidenced-based guidelines for the man-
agement of C. difficile infection. In constituting the expert
panel, the board of World Society of Emergency Surgery
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(WSES) involves many of the world’s leading surgical ex-
perts in management of CDI. This expert panel includes
professionals who treat CDI patients on a daily basis as
well as those with research interests in the condition.
These guidelines outline clinical recommendations based
on the Grading of Recommendations Assessment, Devel-
opment, and Evaluation (GRADE) hierarchy criteria sum-
marized in Table 1 [12, 13].
Recommendations
Diagnosis
1) Stool testing should only be performed on diarrhea
stools from at-risk patients with clinically significant
diarrhea (Recommendation 1 C).
2) For patients with ileus who may be unable to pro-
duce stool specimens, polymerase chain reaction testing
of perirectal swabs may be an accurate and efficient
method to detect toxigenic C. difficile in patients with
symptoms of CDI (Recommendation 2B).
3) Nucleic acid amplification tests (NAAT) such as poly-
merase chain reaction (PCR) for C. difficile toxin genes ap-
pear to be sensitive and specific and may be used as a
standard diagnostic test for CDI. NAAT as single-step
algorithm can increase detection of asymptomatic
colonization therefore it should only be performed in pa-
tients with clinical suspicion for CDI (Recommendation 1
B).
4) Glutamate dehydrogenase (GDH) screening tests for
C. difficile are sensitive but do not differentiate between
toxigenic and non-toxigenic strains. They may be used in
association with toxin A and B EIA testing. Algorithms in-
volving screening with an EIA for GDH followed by a
toxin assay may be used (Recommendation 1 B).
5) Enzyme immunoassay (EIA) for toxin A/B is fast
and inexpensive and has high specificity but it is not rec-
ommended alone due to its relatively low sensitivity.
(Recommendation 1 B).
6) Clostridium difficile culture is relatively slow but
sensitive. It is rarely performed today as a routine diag-
nostic test. C. difficile culture is recommended for subse-
quent epidemiological typing and characterization of
strains (Recommendation 1 C).
7) Repeat testing within 7 days should not be performed
on patients who previously tested negative unless the
clinical picture has changed significantly (Recommenda-
tion 1 C).
Table 1 Grading of recommendations from Guyatt and colleagues [12, 13]
Grade of recommendation Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong recommendation,
high-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs without important limitations
or overwhelming evidence from
observational studies
Strong recommendation, applies
to most patients in most circumstances
without reservation
1B
Strong recommendation,
moderate-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs with important limitations
(inconsistent results, methodological
flaws, indirect analyses or imprecise
conclusions) or exceptionally strong
evidence from observational studies
Strong recommendation, applies to most
patients in most circumstances without
reservation
1C
Strong recommendation, low-quality
or very low-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
Observational studies or case series Strong recommendation but subject to
change when higher quality evidence
becomes available
2A
Weak recommendation,
high-quality evidence
Benefits closely balanced
with risks and burden
RCTs without important limitations
or overwhelming evidence from
observational studies
Weak recommendation, best action may
differ depending on the patient, treatment
circumstances, or social values
2B
Weak recommendation,
moderate-quality evidence
Benefits closely balanced
with risks and burden
RCTs with important limitations
(inconsistent results, methodological
flaws, indirect or imprecise) or
exceptionally strong evidence from
observational studies
Weak recommendation, best action may
differ depending on the patient, treatment
circumstances, or social values
2C
Weak recommendation, Low-quality
or very low-quality evidence
Uncertainty in the estimates
of benefits, risks, and burden;
benefits, risk, and burden may
be closely balanced
Observational studies or case series Very weak recommendation; alternative
treatments may be equally reasonable and
merit consideration
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8) Immunocompromised patients (including patients in
chemotherapy, chronic corticosteroid therapy or immuno-
suppressive agents, and post-transplant patients) should
be always tested for CDI if they have a diarrheal illness
(Recommendation 1 C).
9) CT imaging is suggested for suspected severe-
complicated C. difficile colitis, however its sensitivity is not
satisfactory for screening purposes (Recommendation 2 B).
10) Ultrasound may be useful in critically ill patients
suspected to have pseudomembranous colitis who can-
not be transported for CT scan (Recommendation 2 C).
11) Flexible sigmoidoscopy may be helpful for the diag-
nosis of C. difficile colitis (CDC) when there is a high level
of clinical suspicion for C. difficile despite repeated nega-
tive laboratory assays (Recommendation 2 B).
Antimicrobial therapy
12) Unnecessary antimicrobial agent(s) and proton
pump inhibitors should be discontinued if CDI is sus-
pected (Recommendation 1 C).
13) Empirical therapy for CDI should be avoided un-
less there is a strong suspicion for CDI. If a patient has a
strong suspicion for CDI, empirical therapy for CDI
should be considered while awaiting test results (Recom-
mendation 1 B).
14) Metronidazole is recommended for the treatment
of mild-moderate disease (Recommendation 1 A).
15) Oral vancomycin is recommended for treatment of
patients with severe disease, or for patients with mild-
moderate disease who do not respond to metronidazole.
(Recommendation 1 A).
16) In patients in whom oral antibiotics cannot reach
the colon, vancomycin may be administered by enema
and metronidazole can be given intravenously (Recom-
mendation 1 B).
17) Fidaxomicin may be used to treat CDI, especially in
the patients at higher risk for recurrence (e.g. elderly pa-
tients with severe underlying disease or those requiring re-
ceiving concomitant antibiotics) (Recommendation 1 A).
Surgical management
18) Patients with severe CDI who progress to systemic
toxicity should undergo early surgical consultation and
evaluated for potential surgical intervention (Recom-
mendation 1 C).
19) Resection of the entire colon should be considered
to treat patients with fulminant colitis (FC) (Recommen-
dation 1 B).
20) Diverting loop ileostomy with colonic lavage may
be a useful alternative to resection of entire colon (Rec-
ommendation 2 C).
21) Patients with FC should be treated with high dose
oral or by enema vancomycin (500 mg, 6 hourly) in
combination with intravenous metronidazole (500 mg, 8
hourly). (Recommendation 1 C).
Supportive care
22) Supportive measures, including intravenous fluid re-
suscitation and electrolyte replacement, should be pro-
vided to all patients with severe C. difficile infection
(Recommendation 1 C).
23) Early detection of shock and aggressive manage-
ment of underlying organ dysfunction are essential for
optimum outcomes in patients with fulminant colitis
(Recommendation 1 C).
Recurrent C. difficile infection (RCDI)
24) Agents that may be used to treat the first recurrence
of CDI include metronidazole, for non-severe RCDI, and
vancomycin for severe RCDI. (Recommendation 1 B).
25) Fidaxomicin may be used as an alternative agent
(Recommendation 1 B).
26) In subsequent recurrence of CDI (2nd or later)
oral vancomycin or fidaxomicin is recommended (Rec-
ommendation 1 B).
Probiotics
27) Probiotics may be considered as an adjunctive treat-
ment to antibiotics for immunocompetent patients with
RCDI (Recommendation 2 B).
Faecal microbiota transplantation
28) Intestinal or faecal microbiota transplantation (IMT
or FMT) may be an effective option for the treatment of
RCDI (Recommendation 1 B).
29) FMT may be effective in immunocompromised pa-
tients and patients who have had solid organ transplants
(Recommendation 2 B).
Intravenous immunoglobulin (IVIG)
30) IVIG should only be used as adjunct therapy in pa-
tients with multiple recurrent or fulminant CDI until re-
sults from large, randomized controlled trials are
available (Recurrence 2 C).
Monoclonal antibodies
31) Infusion with monoclonal antibodies may be of use
to prevent recurrences of CDI, particularly in patients
with CDI due to the 027 epidemic strain (Recommenda-
tion 2 C).
Enteral nutrition in CDI
32) Tube feeding patients should be clinically assessed due
to their risk for developing CDI (Recommendation 2 C).
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Anti-motility agents
33) The use of anti-peristaltic agents for the treatment of
CDI should be discouraged. If anti-peristaltic, if used in
isolation agents, are used to control persistent symptoms
in patients with CDI they must always be accompanied by
medical therapy (Recommendation 2 C).
Prevention
34) Proper antimicrobial stewardship in selecting an ap-
propriate antibiotic and optimizing its dose and duration
to cure an infection may prevent the emergence of C.
difficile (Recommendation 1 B).
35) Patients with suspected or proven CDI should be
placed in contact (enteric) precautions (Recommenda-
tion 1 B).
36) Hand hygiene with soap and water is a cornerstone
of the prevention of C. difficile. Hand hygiene, contact
precautions and good cleaning and disinfection of the
environment and patient care equipment, should be
used by all health-care workers contacting any patient
with known or suspected CDI (Recommendation 1 B).
Introduction
C. difficile is an anaerobic, spore forming Gram-positive
bacillus, which may form part of the normal intestinal
microbiota in healthy newborns but which is rarely
present in the gut of healthy adults [14–16]. The organ-
ism is spread via the oral-fecal route and in hospitalized
patients may be acquired through the ingestion of spores
or vegetative bacteria spread to patients by healthcare per-
sonnel’s hands or from the environment [17, 18]. It is the
most common cause of diarrhea in hospitalized patients.
Pathogenesis
Clostridium difficile spores survive the acidic environ-
ment of the stomach and germinate in the intestine [19].
They act as an environmental reservoir for C. difficile
and can facilitate spread among patients, as well as con-
tributing to the high recurrence rates observed in CDI.
The primary toxins produced by this bacterium are
toxins A and B [20]. Some strains of C. difficile also pro-
duce binary toxin. Toxins A and B act as glucosyltrans-
ferases, promoting the activation of Rho GTPases leading
to disorganization of the cytoskeleton of the colonocyte,
and eventual cell death [21]. Since CDI is a toxin mediated
infection, non toxigenic C. difficile strains are non-
pathogenic. Over the years the respective roles and import-
ance toxins A and B has been debated. Toxin A was
thought to be the major virulence factor for many years,
[22–24]. It is now established that both toxins A and B are
important for inducing colonocyte death and colitis. In
addition to toxins A and B, some strains produce a third
toxin known as binary toxin [25–29]. Binary toxin has an
ADP-ribosyltransferase function, which also leads to actin
depolymerization [30, 31]. It has been demonstrated in C.
difficile strains associated with nosocomial outbreaks of
CDI with increased clinical severity [32, 33].
Typing is useful to differentiate C. difficile strains and
to obtain epidemiological information. Different typing
methods for C. difficile are actually available: restriction
endonuclease analysis (REA), pulsed-field gel electro-
phoresis (PFGE), multilocus sequence typing (MLST),
repetitive-element PCR typing, toxinotyping, multilocus
variable-number tandem-repeat analysis (MLVA) and
PCR- ribotyping [34].
C. difficile strains with increased virulence traits (hyper
virulent), have been described in the last 10 years. In par-
ticular, PCR-ribotype 027, also known as North American
pulsed-field gel electrophoresis type 1 (NAP1) or restric-
tion endonuclease analysis group BI, has been associated
with increased disease severity, recurrence and significant
mortality [35].
Asymptomatic colonization may occur in 6 to 50 % of
long-term care facility residents depending on whether
CDI is endemic [36, 37]. In a 15-month prospective study
of 4143 patients performed in six Canadian hospitals in
Quebec and Ontario [38], 184 (4.4 %) had asymptomatic
colonization at the time of unit admission, and 123 (3.0 %)
had health care–associated C. difficile colonization.
Risk factors
Risk factors for CDI may be divided into three general
categories: host factors (immune status, co-morbidities),
exposure to CD spores (hospitalizations, community
sources, long-term care facilities) and factors that dis-
rupt normal colonic microbiome (antibiotics, other med-
ications, surgery) [39].
Host factors
Risk factors identified to date include, age more than
65 years, comorbidity or underlying conditions, inflam-
matory bowel diseases, immunodeficiency (including hu-
man immunodeficiency virus infection, hematologic
malignancies and chemotherapy), malnutrition, and low
serum albumin level [3, 40]. Diabetes mellitus is increas-
ingly recognized as a risk factor for hospital and
community-acquired CDI [41]. More recently, gene
polymorphisms (e.g. IL-8) may be associated with in-
creased risk for CDI but further studies are needed [42].
The effect of prior appendectomy on the development
of C. difficile colitis has been debated in literature [43].
A recent review by Seretis et al. [44] of five studies
conducted retrospectively was published in 2014. Al-
though the results were conflicting regarding the impact
of prior appendectomy on the occurrence or relapse of
CDI, it appeared that an in situ appendix did not impact
on the development of CDI.
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In the retrospective analysis by Clanton et al. [45] on
55 patients who underwent colectomy for CDI between
2001 and 2011, a prior appendectomy was noted in 24
of 55 specimens (44, 99 % CI: 0.280–0.606). This was
compared to an observed lifetime rate of appendectomy
of 17.6 %. The rate of appendectomy in the cohort of
patients who later underwent colectomy for CDI was
significantly higher than would be expected in the gen-
eral population (44 % vs 18 %, P < 0.01).
In a second retrospective study [46], of 388 patients
with an intact appendix, 20 (5.2 %) developed fulminant
infection and required colectomy, whereas of the 119
patients with a previous appendectomy, 13 (10.9 %) re-
quired colectomy. An increased severity of disease, indi-
cated by increased rate of colectomy, occurred for the
group with a history of appendectomy (P = 0.03).
A sub-group analysis of a large population based study
published in 2013 [47] showed that appendectomy was
not associated with adverse outcomes in CDI. Patients
with appendectomy before CDI had no differences in
risk factors, treatment, or outcomes including treatment
failure, development of severe or severe-complicated
CDI, and recurrence rates as compared with patients
without appendectomy.
Larger prospective studies are needed to assess the im-
pact of prior appendectomy on development and sever-
ity of CDI.
Exposure to Clostridium difficile spores
Factors that increase risk of exposure to C. difficile
spores, such as increased duration of hospital stay may
increase the risk of CDI. A length of stay > 2 weeks has
been shown to be a risk factor for CDI [48]. Hospitals
with well implemented infection prevention and control
measures may reduce the risk of patients of developing
CDI [49].
Normal flora disruption
The indigenous gut microbiota is the complex community
of microorganisms that populates the gastrointestinal
tract. This micro-ecosystem plays a crucial role in protect-
ing the intestines by providing resistance to colonization
and infection by pathogenic organisms [50]. Gut micro-
biota also has immeasurable effects on homeostasis in the
host [51]. Under normal conditions, the human gut
microbiota may impede pathogen colonisation through
general mechanisms such as direct inhibition through bac-
teriocins, nutrient depletion (consuming growth-limiting
nutrients) or stimulation of host immune defences [38]
though the exact mechanism by which the microbiota
protects against CDI is unknown [52]. Disruption of the
normal balance of colonic microbiota as a consequence of
antibiotic use or other stressors, is, however, likely to be
important [53].
Antibiotic exposure
It is presumabed that disruption of the normal gut flora
provides a perfect setting for C. difficile to proliferate
and produce toxin.
The risk of CDI is increased up to 6-fold during and
in the subsequent month after antibiotic therapy [54].
Although nearly all antibiotics have been associated with
CDI, clindamycin, third-generation cephalosporins, peni-
cillins and fluoroquinolones have traditionally been con-
sidered to pose the greatest risk [55–61]. An association
between CDI and antimicrobial treatment > 10 days has
also been demonstrated [62, 63]. Antibiotics which have
been less commonly associated with CDI include macro-
lides, sulfonamides and tetracyclines [64]. Even very lim-
ited exposure, such as single-dose surgical antibiotic
prophylaxis may increase patients risk for both C. diffi-
cile colonization [65, 66] or infection.
Other medications
Exposure to gastric acid-suppressive medications, such
as histamine-2 blockers and proton pump inhibitors
(PPIs) may be a potential risk factor for development of
CDI. Recent studies have suggested the association be-
tween use of stomach acid–suppressive medications, pri-
marily PPIs, and CDI [67, 68]. In 2012 a systematic
review of [69] 42 observational studies (30 case–control,
12 cohort) totalling 313,000 participants were evaluated
for incident and recurrent CDI in PPI users. Despite the
substantial statistical and clinical heterogeneity, the find-
ings indicated a probable association between PPI use
and incident and recurrent CDI. This risk was further
increased by concomitant use of antibiotics and PPI.
Other studies suggested that this association may be the
result of confounding with the underlying severity of ill-
ness and duration of hospital stay [70]. Given that acid
suppression drugs, especially PPIs, may be over- pre-
scribed in surgical settings consideration should be given
to stopping PPIs in patients at high risk of CDI.
Surgery
Recent reports have linked the development of CDI in
surgical patients with widespread use of broad-spectrum
antibiotics, increasing numbers of elderly and immuno-
compromised patients undergoing surgical interventions
and the emergence of more virulent strains of C. difficile
[8, 71, 72].
Abdelsattar et al. [11] prospectively identified patients
with laboratory-confirmed postoperative CDI after differ-
ent general, vascular, or gynaecological surgeries at 52 aca-
demic and community hospitals in the state of Michigan,
USA between July 2012 and September 2013. The highest
rates of CDI occurred after lower-extremity amputation
(2.6 %), followed by bowel resection or repair (0.9 %) and
gastric or esophageal operations (0.7 %). Gynaecological
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and endocrine operations had the lowest rates (0.1 and
0 %, respectively). Using multivariable analyses, older
age, chronic immunosuppression, hypoalbuminemia
(≤3.5 g/dL) and preoperative sepsis were associated with
CDI. Use of prophylactic antibiotics was not independ-
ently associated with CDI, neither was sex, body mass
index (BMI), surgical priority, weight loss, or comorbid
conditions.
Zerey et al. [8] performed a five-year retrospective
analysis of the Agency for Healthcare Research and
Quality’s National Inpatient Sample Database represent-
ing a stratified 20 % sample of hospitals in the United
States, from 1999 to 2003. Patients undergoing an emer-
gency operation were at higher risk of CDI than those
having operations performed electively. Colectomy,
small-bowel resection, and gastric resection were asso-
ciated with the highest risk of CDI. Patients undergoing
cholecystectomy and appendectomy had the lowest risk.
In 2010, Rodriguez et al. [73] published a retrospective
analysis of all general surgery inpatients admitted to a
large tertiary referral general surgical unit in the United
Kingdom, between March 2005 and May 2007. Multi-
variate analysis identified malignancy, gastrointestinal
disease, anemia, respiratory disease, circulatory disease,
diabetes mellitus, those undergoing gastrointestinal sur-
gery and increasing age to be independently associated
with C. difficile.
To assess risk factors associated with CDI on a surgi-
cal ward, in 2012 Kim et al. conducted a retrospective
chart review of all patients admitted between January
2010 and July 2011 [74]. The rate of CDI occurrence
was 0.4 % (19/4,720 patients). Multivariate analysis
showed that colectomy and hospital stays longer than
10 days were the highest risk factors for CDI occurrence
in the surgical ward.
Using the Japanese Diagnosis Procedure Combination
inpatient database, Yasunaga et al. [75] analyzed factors af-
fecting the occurrence of CDI and the outcomes of CDI
following digestive tract surgery. Of 143,652 patients
undergoing digestive tract surgery, CDI was identified in
409 (0.28 %) patients. High mortality, long hospital stay
and high costs were associated with postsurgical CDI.
Colo-rectal surgery is known as risk factor for CDI in
surgical patients [76, 77]. Recently Damle et al. [78] pub-
lished a retrospective analysis of patients who developed
CDI following colorectal resection. Utilizing the U.S.
University Health System Consortium database the au-
thors identified adult patients undergoing colorectal sur-
gery between 2008 and 2012. A total of 84,648 patients
met study inclusion criteria. CDI occurred in 1,266
(1.5 %) patients during the study period. The strongest
predictors of CDI were emergency procedure, inflamma-
tory bowel disease, and severity of illness score. CDI was
associated with a higher rate of complications, intensive
care unit (ICU) admission, longer preoperative inpatient
stay, 30-day readmission rate, and death within 30 days
compared to non-CDI patients.
In 2008 Lumpkins et al. [79] published a retrospective
observational study about the incidence of CDI in the
critically injured trauma population. Five hundred
eighty-one consecutive critically injured trauma patients
were followed prospectively for development of CDI, di-
agnosed by toxin assay. Among 581 patients 19 cases of
CDI were diagnosed (3.3 %). Intensive care unit length
of stay, ventilator days, and hospital length of stay were
significantly higher in the CDI patients. The diagnosis
was made at mean of 17 days after admission; however,
in four patients (21 %), the infections were diagnosed
within six days of admission. Fourteen patients (74 %)
had received therapeutic antibiotics for confirmed or
suspected infection prior to the appearance of colitis;
four patients (21 %) received only intraoperative prophy-
laxis, and one patient had no antibiotic exposure.
Recently Egorova et al. [80] reviewed the trend, hos-
pital variability in CDI rates, in vascular surgery in USA.
The rates of CDI after major vascular procedures includ-
ing aortic abdominal aneurysm (AAA) repair, carotid
endarterectomy or stenting, lower extremity revasculari-
zation (LER), and LE amputation were identified using
Nationwide Inpatient Sample database for 2000–2011.
During the study period the rates of CDI after vascular
procedures had increased by 74 % from 0.6 in 2000 to
1.05 % in 2011. In 2011, the highest rates were after rup-
tured AAA repair (3.3 %), followed by lower extremity
amputations (2.3 %), and elective open AAA (1.3 %).
Iinflammatory bowel disease (IBD)
Patients with inflammatory bowel disease (IBD) may
have increased risk of developing CDI, along with worse
outcomes, higher rates of colectomy and higher rates of
recurrence [81–84]. Patients with IBD also appear to
have higher rates of asymptomatic carriage of C. difficile
[85]. They receive various types of immunosuppressive
drugs including steroids that has been found to increase
the risk of CDI [86, 87].
The clinical presentation of an IBD exacerbation and
CDI often is indistinguishable and requires a high index of
suspicion for adequate treatment [6]. As the symptoms of
CDI and an exacerbation of IBD (diarrhea, abdominal
pain, fever and leukocytosis) overlap, the diagnosis of CDI
may be delayed if it is not tested for [88]. In addition, in
IBD patients with ileostomies, the development of acute
enteritis as manifested by an increase in ileostomy output,
nausea, fever and leukocytosis may also indicate CDI. The
same is true for pouchitis, which presents as an increase
in the number of stools per day [89]. In one study 10.7 %
of patients with ileal pouch anal anastomosis, presenting
with pouchitis, were found to have CDI [90].
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In patients with IBD and severe colitis, empirical ther-
apy directed against both CDI and treatment of an IBD
flare should be started simultaneously while awaiting re-
sults of C. difficile testing [6].
Due to high rates of asymptomatic colonization of C.
difficile in patients with IBD, only patients with in-
creased diarrhea or new symptoms attributable to CDI
should be tested for C. difficile toxin. Typical findings of
CDI on colonoscopy are often absent in patients with
IBD (0–13 % of cases) [91] which may be attributed to a
weakened inflammatory response. There is no evidence
from prospective studies to suggest that one antibiotic
regimen is better than another for the treatment of CDI in
IBD patients. Considering the worse outcomes seen in pa-
tients with IBD and CDI, some institutions use vanco-
mycin as first line therapy. In a survey of North American
gastroenterologists, there was no agreement on combin-
ation of antibiotics and immunomodulators in patients
with an IBD flare and CDI [92]. The American College of
Gastroenterology recommended with low quality support-
ing evidence, that ongoing immunosuppression can be
maintained in patients with CDI but escalation of im-
munosuppression should be avoided.
Physicians should remain alert to the possibility of
CDI in a patient with an IBD exacerbation to ensure
rapid diagnosis and treatment. Early surgical consult-
ation is also key for improving outcomes of patients with
severe disease. Colectomy with preservation of the rec-
tum may need to be considered for severely ill IBD pa-
tients with CDI.
Immunocompromise patients
It is well known that the rate of CDI in the post-
transplant setting is higher [93]. It has also been re-
ported that cancer patients have a higher risk compared
with non-cancer patients [94] due to chemotherapy
causing the immunosuppression. Recently two retro-
spective studies were published on CDI in cancer pa-
tients [95, 96].
In the first a total of 225 patients were included, and
39 of them (17.3 %) were diagnosed with CDI. Type of
tumor significantly differed between CDI patients, thus
relative risk in each type of cancer was calculated after
adjusting for age, antibiotic exposure, corticosteroid, and
proton-pump inhibitor use. Patients with gastrointestinal
tumors were less prone to CDI. Conversely, breast can-
cer patients have a greater predisposition to CDI. Anti-
biotic treatment was found to be associated with an
increasing risk for CDI in breast cancer patients [95].
In the second study of 277 cancer patients with diar-
rhea 41 (14.8 %) were C. difficile toxin-positive. Multi-
variate analysis showed that chemotherapy (OR, 8.308;
95 % CI, 1.997–34.572; P = 0.004) and a positive result
of fecal occult blood test (OR, 8.475; 95 % CI, 1.463–
49.109; P = 0.017) were independent risk factors for ac-
quisition of CDI among cancer patients [96].
Patients with HIV/AIDS are at a high risk of being in-
fected with C. difficile too. This relationship is stronger
in those with low absolute CD4 T cell counts or who
meet clinical criteria for an AIDS diagnosis [97].
The increased risk may be partially attributed to fre-
quent hospitalization, exposure to antibiotics and anti-
biotic prophylaxis for opportunistic infections, but HIV
related alterations in fecal microbiota, gut mucosal in-
tegrity, and humoral and cell mediated immunity may
be also likely to play a role [98].
Community-acquired C. difficile infection (CA-CDI)
Community-acquired CDI (CA-CDI) has been demon-
strated in populations previously thought to be at low-
risk, including younger patients not previously exposed
to antibiotics [99]. Suggested risk factors include in-
creasing outpatient antibiotic prescriptions, greater use
of acid-suppression medications, an increase in the pro-
portion of asymptomatic carriers in the community and
novel risk factors like food and water contamination
[100]. A sub-group analysis of a population-based epi-
demiological study of CDI in Olmsted County, Minne-
sota from 1991–2005 was published in 2012 [101]. Of
157 CA-CDI cases, the median age was 50 years and
75.3 % were female. Among CA-CDI cases, 40 % re-
quired hospitalization, 20 % had severe and 4.4 % had
severe-complicated infection, 20 % had treatment failure
and 28 % had recurrent CDI.
Recently a systematic review and meta-analysis investi-
gated the association between commonly prescribed medi-
cations and comorbidities with CA-CDI [41]. Twelve
publications (n = 56,776 patients) met inclusion criteria.
Antimicrobial (odds ratio, 6.18; 95 % CI 3.80–10.04) and
corticosteroid (1.81; 1.15–2.84) exposure were associated
with increased risk of CA-CDI. Among the comorbidities,
inflammatory bowel disease (odds ratio, 3.72; 95 % CI,
1.52–9.12), renal failure (2.64; 1.23–5.68), hematologic can-
cer (1.75; 1.02–5.68), and diabetes mellitus (1.15; 1.05–
1.27) were associated with CA-CDI. By location, antimicro-
bial exposure was associated with a higher risk of CA-CDI
in the United States, whereas proton-pump inhibitor ex-
posure was associated with a higher risk in Europe. By life
stages, the risk of CA-CDI associated with antimicrobial
exposure greatly increased in adults older than 65 years.
Risk factors for recurrent CDI
In a meta-analysis by Garey et al. [102] found that con-
tinued use of non-C. difficile antibiotics after diagnosis
of CDI (OR: 4.23; 95 % CI: 2.10–8.55; P < 0.001), con-
comitant receipt of antacid medications (OR: 2.15; 95 %
CI: 1.13–4.08; P = 0.019), and older age (OR: 1.62; 95 %
CI: 1.11–2.36; P = 0.0012) were significantly associated
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with an increased risk of recurrent CDI. Other factors
identified in individual studies include age, hospital ex-
posure, comorbid conditions, severe underlying illness,
poor quality of life scores, initial disease severity and
previous recurrent CDI [103, 104].
A recent systematic review and meta-analysis [105]
was published to evaluate current evidence on the
risk factors for recurrent CDI. A total of 33 studies
(n = 18,530) met the inclusion criteria. The most fre-
quent independent risk factors associated with recur-
rent CDI were age ≥65 years (risk ratio [RR], 1.63;
95 % confidence interval [CI], 1.24–2.14; P = .0005),
additional antibiotics during follow-up (RR, 1.76; 95 % CI,
1.52–2.05; P < .001), use of proton-pump inhibitors (PPIs)
(RR, 1.58; 95 % CI, 1.13–2.21; P = .008), and renal insuffi-
ciency (RR, 1.59; 95 % CI, 1.14–2.23; P = .007). The risk
was also greater in patients previously on fluoroquino-
lones (RR, 1.42; 95 % CI, 1.28–1.57; P < .001).
Clinical manifestations
The spectrum of symptomatic CDI ranges from mild diar-
rhea to severe disease or fulminant colitis and as many as
30 % of patients may develop recurrent CDI [106, 107].
Though diarrhea is the hallmark symptom of CDI it
may not be present initially, possibly due to colonic dys-
motility either from previous underlying conditions or
possibly from the disease process itself [108].
This is especially important in surgical patients who
may have a concomitant ileus. Therefore, in surgical pa-
tients it is important to have a high index of suspicion
for the development of CDI.
Mild-moderate CDI
Diarrhea may be accompanied by mild abdominal pain
and cramps and if prolonged may result in altered elec-
trolyte balance and dehydration. When this occurs in
patients with severe comorbidity, particularly after sur-
gery, non-severe CDI may increase morbidity signifi-
cantly [109].
Severe CDI
Severe CDI is associated with increased abdominal
cramping and pain and constitutional features such as
fever, leukocytosis, and hypoalbuminemia. The absence
of diarrhoea in these patients may signal a progression
to fulminant infection [110]. Though a wide variety of
severity predictors for severe CDI has been described
[111–115] international consensus for the definition of
severe CDI is lacking [6, 7, 116].
One systematic review identifying risk factors for ad-
verse outcomes of CDI was published by Abou Chakra
et al. in 2012 [114]. Except for leukocytosis, albumin and
age, there was much heterogeneity in the data and most
studies were limited by small sample sizes.
To investigate the prognostic value of fever, leukocytosis,
and renal failure, Bauer et al. [113] in 2012 analyzed the
database of two randomized controlled trials, which con-
tained information for 1105 patients with CDI. They found
that both leucocytosis and renal failure were useful predic-
tors of a complicated course of CDI. Miller et al. [115] in
2013 subsequently published an analysis of the same two
clinical therapeutic trials to validate a categorization sys-
tem to stratify CDI patients into severe or mild-moderate
groups. A combination of five simple and commonly avail-
able clinical and laboratory variables (ATLAS) measured
at the time of CDI diagnosis were able to accurately pre-
dict treatment response to CDI therapy. The ATLAS cri-
teria included: age, treatment with systemic antibiotics,
leucocyte count, albumin and serum creatinine [115].
Any of the following may be predictors of severe CDI:
 WBC >15 × 109/L
 Acutely rising serum creatinine
 Temperature >38.5 °C
 Albumin <2.5 mg/dL
The progression to fulminant C. difficile colitis is rela-
tively infrequent [109] (1–3 % of all CDI) although mor-
tality in this group of patients remains high due to the
development of toxic megacolon with colonic perfor-
ation, peritonitis and septic shock and subsequent organ
dysfunction. Systemic symptoms may result from toxin-
induced inflammatory mediators released locally in the
colon [117–119]. Studies have demonstrated a significant
rise in the number of cases of fulminant colitis associated
with multiple organ failure and increased mortality in re-
cent years associated with the hypervirulent 027 strain of
C. difficile [120, 121]. Early diagnosis and treatment is
therefore important in reducing the mortality associated
with fulminant colitis. Patients who present with organ
failure including increased serum lactate or vasopressor
requirements, should be assessed immediately with regard
to early operative intervention [121].
Recurrent CDI (RCDI)
Recurrence of symptoms after initial therapy for C. diffi-
cile, develops in 10–30 % of cases, and this often pre-
sents a clinical challenge. Patients may have several
episodes of recurrence that may occur over a period of
years [122–127]. Recurrence and reinfection are there-
fore difficult to distinguish by symptoms alone, but may
be distinguished if the strain of C. difficile is typed.
RCDI may be either a consequence of germinating
resident spores remaining in the colon after antibiotic
treatment has stopped, or re-infection from an environ-
mental source.
Even though consensus regarding factors associated
with CDI recurrence is not universal learning algorithms
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have been developed to predict CDI recurrence with
good sensitivity [128].
Ultimately distinction between recurrence and reinfec-
tion can only be achieved if the strain of C. difficile is
‘typed’ using molectular epidemiology [129].
Wider consequences of CDI
Patients who develop CDI have increased hospital
length-of-stay, higher medical care costs, more hospital
re-admissions, and higher mortality [130–132].
These consequences are also found for surgical pa-
tients with CDI.
In the Zerey et al. analysis [8] epidemiologic data sug-
gested that the infection was most prevalent after emer-
gency operations and among patients having intestinal
tract resections. Infection with C. difficile was an inde-
pendent predictor of increased length of stay, which in-
creased by 16.0 days (95 % CI 15.6, 16.4 days; p < 0.0001)
in the presence of infection. Total charges increased by
$77,483 (95 % CI $75,174, $79,793; p < 0.0001), and
there was a 3.4-fold increase in the mortality rate (95 %
CI 3.02, 3.77; p < 0.0001) compared with patients who
did not acquire C. difficile.
In the Abdelsattar et al. study [11] three procedure
groups had higher odds of postoperative CDI: lower-
extremity amputations (adjusted odds ratio [aOR],
3.5; P = .03), gastric or esophageal operations (aOR,
2.1; P = .04), and bowel resection or repair (aOR, 2;
P = .04). Postoperative CDI was independently associ-
ated with increased length of stay (mean, 13.7 days
vs 4.5 days), emergency department presentations
(18.9 vs 9.1 %) and readmissions (38.9 vs 7.2 %, all
P < .001).
Data from Nationwide Inpatient Sample database in pa-
tients who underwent vascular surgery [79], showed that
in 2011 patients who had experienced CDI had median
length of stay 15 days (IQR 9, 25 days) compared with
8.3 days for matched patients without CDI, in-hospital
mortality 9.1 % (compared to 5.0 %), and $13,471 extra
cost per hospitalization. The estimated cost associated
with CDI in vascular surgery in the United States was
about $98 million in 2011. Data from the National In-
patient Sample examined just patients with lumbar sur-
gery and found CDI increased length of stay by 8 days,
hospital costs by 2-fold and increased inpatient mortality
by 36-fold [133].
Higher mortality was also observed for liver transplant
recipients (from 2000 to 2010) at Detroit hospital [134].
The ACS-NSQIP database from 2005 to 2010 was
used by Lee et al. to study emergently performed open
colectomies for a primary diagnosis of C difficile colitis
in US [135]. The overall mortality was 33 % (111/335). Age
80 years or older, preoperative dialysis dependence, chronic
obstructive pulmonary disease), and wound class III were
associated to patients mortality. Thrombocytopenia (plate-
let count < 150 × 103/mm3), coagulopathy (International
Normalized Ratio > 2.0), and renal insufficiency (blood urea
nitrogen > 40 mg/dL) were associated with a higher mortal-
ity as well.
Recently a study was performed to quantify additional
hospital stay attributable to CDI in four European coun-
tries, by analyzing nationwide hospital-episode data [5].
Patients in England had the longest additional hospital
stay attributable to CDI at 16.09 days, followed by
Germany at 15.47 days, Spain at 13.56 days, and The
Netherlands at 12.58 days, derived using regression ana-
lysis. Propensity score matching indicated a higher at-
tributable length of stay of 32.42 days in England,
15.31 days in Spain, and 18.64 days in The Netherlands.
Outputs from this study consistently demonstrate that
in European countries, for patients whose hospitalization
is complicated by CDI, the infection causes a statistically
significant increase in hospital length of stay.
Recommendations for the management of CDI
Diagnosis
1) Stool testing should only be performed on diar-
rhea stools from at-risk patients with clinically sig-
nificant diarrhea (Recommendation 1 C).
2) For patients with ileus who may be unable to
produce stool specimens, polymerase chain reaction
testing of perirectal swabs may be an accurate and ef-
ficient method to detect toxigenic C. difficile in pa-
tients with symptoms of CDI (Recommendation 2B).
Prompt and precise diagnosis is important for the ef-
fective management of CDI.
Early identification of CDI allows early treatment and
can potentially improve outcomes. Rapid isolation of in-
fected patients is important in controlling the transmis-
sion of C. difficile [136].
The diagnosis of CDI is based on the presence of a
clinical picture compatible with CDI and microbiological
evidence of free toxin and/or the demonstration of toxi-
genic C. difficile in a diarrhea stool sample [136]. Clin-
ical features include: diarrhea (defined as by passage of 3
or more unformed stools in 24 h), abdominal pain and
cramps, abdominal distension, ileus (signs of severely
disturbed bowel function) and toxic megacolon.
Since C. difficile can colonize the intestinal tract of
healthy individuals, diagnostic testing for CDI should be
performed only on diarrhea stools from symptomatic pa-
tients. Testing of formed stool can result in false positive
tests, which may result in unnecessary antibiotic therapy.
One limitation of the reliance on stool specimens are
the patients with suspected severe CDI complicated by
ileus as these patients may be unable to produce speci-
mens for testing. For these patients testing of perirectal
swabs may be an accurate and efficient method to detect
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toxigenic C. difficile. In 2012 Kundrapu et al. [137] de-
scribed the results of a prospective study of 139 patients
being tested for Clostridium difficile infection by poly-
merase chain reaction. The sensitivity, specificity, posi-
tive predictive value, and negative predictive value of
testing perirectal swabs were 95.7, 100, 100, and 99.1 %,
respectively. The authors concluded that for selected pa-
tients, perirectal swabs provided an acceptable alterna-
tive to stool specimen analysis. Clinical context such as
a history of recent antibiotic administration and/or resi-
dence in hospital are useful in selecting patients for test-
ing. Other signs such as fever, abdominal pain,
leukocytosis, in combination with other laboratory tests
(e.g. creatinine and serum lactate) are useful for defining
severity of infection.
3) Nucleic acid amplification tests (NAAT) such
as polymerase chain reaction (PCR) for C. difficile
toxin genes appear to be sensitive and specific and
may be used as a standard diagnostic test for CDI.
NAAT as single-step algorithm can increase detection
of asymptomatic colonization therefore it should only
be performed in patients with clinical suspicion for
CDI (Recommendation 1 B).
4) Glutamate dehydrogenase (GDH) screening tests
for C. difficile are sensitive but do not differentiate
between toxigenic and non-toxigenic strains. They
may be used in association with toxin A and B EIA
testing. Algorithms involving screening with an EIA
for GDH followed by a toxin assay may be used (Rec-
ommendation 1 B).
5) Enzyme immunoassay (EIA) for toxin A/B is fast
and inexpensive and has high specificity but it is not
recommended alone due to its relatively low sensitiv-
ity. (Recommendation 1 B).
6) Clostridium difficile culture is relatively slow
but sensitive. It is rarely performed today as a rou-
tine diagnostic test. C. difficile culture is recom-
mended for subsequent epidemiological typing and
characterization of strains (Recommendation 1 C).
7) Repeat testing within 7 days should not be per-
formed on patients who previously tested negative
unless the clinical picture has changed significantly
(Recommendation 1 C).
The best standard laboratory test for diagnosis of CDI
has not been clearly established [138]. In the past, toxi-
genic culture (TC) was accepted by many microbiolo-
gists as the method of choice for diagnosis of CDI. The
procedure includes stool culture for C. difficile on a se-
lective differential medium (cycloserine, cefoxitin, fruc-
tose agar or CCFA) and an assay to test the colonies for
the ability to produce toxins. Despite the fact that TC is
considered a gold standard method, there are significant
issues including slow turnaround time and it’s inability
to detect the presence of toxins in stool. This may also
lead to false positive results given up to 7 % of asymp-
tomatic hospitalized patients may be colonized with
toxigenic C. difficile [139].
However, TC can still be used as a confirmatory test
in symptomatic patients with toxin positive/GDH as-
say(s)-negative stool samples. C. difficile culture is also
necessary for subsequent epidemiological typing and
characterization of strains.
The EIA for toxin A/B has been adopted by most clin-
ical laboratories because it is fast, convenient and inexpen-
sive [140]. However, studies have shown that sensitivity
can be low. Toxin A + B EIA tests have a described sensi-
tivity of 32–98 % and a specificity of 84–100 % [141].
Glutamate dehydrogenase (GDH) is an enzyme pro-
duced by C. difficile in relatively large amounts com-
pared with toxins A and B [142, 143]. A positive GDH
assay only documents the presence of C. difficile but it
does not discriminate between toxigenic and non-
toxigenic strains (about 20 % of the C. difficile popula-
tion). Therefore, a second test for toxin production is
necessary for confirmation. GDH screening tests for C.
difficile used in association to toxin A + B EIA testing
gives an accurate test result quickly [140, 141] even if
the sensitivity of such strategy is lower than nucleic acid
amplification tests (NAATs).
NAATs such as PCR for CD toxin genes have a high
sensitivity and specificity, but not all laboratories rou-
tinely perform this assay [143]. A current topic of debate
is whether a stool sample that was positive by a molecu-
lar assay needs to be tested with a confirmatory toxin
assay [144] given it can also identify toxigenic C difficile
in asymptomatic patients. This underscores the import-
ance of only testing patients with symptoms. There is no
evidence suggesting that surgical patients should be di-
agnosed any differently than general medical patients.
8) Immunocompromised patients (including patients
in chemotherapy, chronic corticosteroid therapy, or
immunosuppressive agents, and post-transplant pa-
tients) should be always tested for CDI if they have a
diarrheal illness (Recommendation 1 C).
It has already been highlighted that immunocomprom-
ised patients including those on glucocorticoids, or
chemotherapy and post-transplant patients are at in-
creased risk for CDI.
9) CT imaging is suggested for suspected severe-
complicated C. difficile colitis, however its sensitivity
is not satisfactory for screening purposes (Recom-
mendation 2 B).
CT has been studied as an imaging modality for diag-
nosing C. difficile colitis [145–148]. Typical CT findings
of CDC include colonic wall thickening, dilation, perico-
lonic stranding, “accordion sign” (high-attenuation oral
contrast in the colonic lumen alternating with low-
attenuation inflamed mucosa), “double-halo sign, target
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sign” (intravenous contrast displaying varying degrees of
attenuation caused by submucosal inflammation and
hyperemia), and ascites [149]. However, the most com-
mon finding, colonic wall thickening is non-specific and
can be found in other forms of colitis, although it may
be more pronounced in that caused by C. difficile.
In the Kirkpatrick et al. study [150], CT diagnosis of
CDC was made with a sensitivity of 52 %, a specificity of
93 %, and positive and negative predictive valued 88 %,
and 67 % respectively. Sensitivity would have been in-
creased to 70 % with no change in specificity if a colon
wall thickness of greater than 4 mm had been used, in
conjunction with the presence of colon wall nodularity,
accordion sign, peri-colonic stranding, or otherwise un-
explained ascites.
10) Ultrasound may be useful in critically ill pa-
tients suspected to have pseudomembranous colitis
who cannot be transported for CT scan (Recommen-
dation 2 C).
Point-of-care ultrasound may be useful in diagnosing
and managing critically ill patients who cannot be
moved to the radiology department [151].
Ultrasound findings of pseudomembranous colitis in
severe cases include a thickened colonic wall with het-
erogeneous echogenity and narrowing of the colonic
lumen [152]. Pseudomembranes can also be visualised as
hyperechoic lines covering the mucosa [152–155].
In the early stages of pseudomembranous colitis, the
texture of the colonic wall is preserved. The hypoechoic
edematous mucosa and muscularis propria may be
thickened with the echogenic submucosa sandwiched
between them. The presence of submucosal gaps may
indicate extension of tissue damage into deeper struc-
tures. Intraperitoneal free fluid is seen in more than
70 % of cases [153–155].
11) Flexible sigmoidoscopy may be helpful for the
diagnosis of C. difficile colitis (CDC) when there is a
high level of clinical suspicion for C. difficile despite
repeated negative laboratory assays (Recommenda-
tion 2 B).
Endoscopy should be used sparingly to confirm the
diagnosis of C. difficile colitis since the diagnosis can be
usually made by laboratory tests, clinical findings and
imaging. Moreover colonoscopy may be hazardous in
the setting of fulminant colitis where there may be in-
creased risk of perforation [156].
A study by Johal et al. [157] described the use of flexible
sigmoidoscopy as a tool for the diagnosis of C. difficile col-
itis when stool assays were negative. Of 136 patients with
C. difficile associated diarrhea (CDAD) 56 patients had
pseudomembranous colitis at sigmoidoscopy. The stool C.
difficile cytotoxin test was negative in 29 (52 %) but toxi-
genic C. difficile was isolated from all of nine stool sam-
ples cultured. Of patients with pseudomembranous colitis,
30.4 % relapsed over the subsequent 57.7 days. The au-
thors concluded that sigmoidoscopy should be considered
in all hospitalised patients with diarrhea in whom the stool
tests for C. difficile cytotoxin and enteric pathogens are
negative.
Emergency colonoscopy or sigmoidoscopy may also
reveal pseudomembranous colitis in patients too ill to
wait for laboratory results.
Antimicrobial therapy
12) Unnecessary antimicrobial agent(s) and proton
pump inhibitors should be discontinued if CDI is
suspected (Recommendation 1 C).
13) Empirical therapy for CDI should be avoided
unless there is a strong suspicion for CDI. If a patient
has a strong suspicion for CDI, empirical therapy for
CDI should be considered while awaiting test results
(Recommendation 1 B).
In cases of suspected severe CDI, antimicrobial agent(s)
should be discontinued, if possible [158].
A meta-analysis addressing factors associated with
prolonged symptoms and severe disease due to Clostrid-
ium difficile showed that continued use of antimicrobials
for infections other than CDI is significantly associated
with an increased risk of CDI recurrence [159].
When antimicrobial therapy is indicated for symptom-
atic cases with a positive C. difficile toxin result, options
include metronidazole, oral or intraluminal vancomycin
and fidaxomicin [160–166].
14) Metronidazole is recommended for the treatment
of mild-moderate disease (Recommendation 1 A).
Given at a dose of 500 mg orally 3 times a day for
10 days, metronidazole has been shown to be an inex-
pensive and effective treatment of non-severe CDI
[167]. Metronidazole can also be administrated intra-
venously with or without intraluminal vancomycin in
patients unable to take oral medication e.g. those with
post-surgical ileus.
A Cochrane analysis published in 2011 [167] reviewed
15 studies on the antibiotic treatment for CDI in adults.
In three randomized controlled trials comparing symp-
tomatic cure between metronidazole and vancomycin,
no statistically significant difference was found [167].
Symptomatic cure was achieved in 79 % of patients who
received vancomycin compared with 71 % of patients
who received metronidazole (three studies; 335 patients;
RR 0.91; 95 % CI 0.81–1.03, p 0.14).
15) Oral vancomycin is recommended for treatment
of patients with severe disease, or for patients with
mild-moderate disease who do not respond to metro-
nidazole. (Recommendation 1 A).
Vancomycin orally 125 mg four times daily for 10 days
is considered superior to metronidazole in severe C. dif-
ficile disease [168–170]. This may reflect the superior
Sartelli et al. World Journal of Emergency Surgery  (2015) 10:38 Page 11 of 23
pharmacokinetic properties of vancomycin which is con-
centrated in the gut lumen. Doses of up to 500 mg have
been used in some patients with severe CDI [7] although
there is little evidence for this in the literature.
16) In patients in whom oral antibiotics cannot
reach the colon, vancomycin may be administered by
enema and metronidazole can be given intravenously
(Recommendation 1 B).
Intravenous vancomycin has no effect on CDI since
the antibiotic is not excreted into the colon. Vancomycin
enema may be an effective therapy for patients who can-
not tolerate the oral preparation or patients with ileus
who have delayed passage of oral antibiotics from the
stomach to the colon. Trans-stoma vancomycin may
also be effective in surgical patients with Hartmann re-
section, ileostomy, or colon diversion. A single-hospital,
retrospective chart review on 47 consecutive patients
with C. difficile colitis treated with intra-colonic vanco-
mycin (ICV) was published by Kim PK et al. in 2013
[171]. Thirty-three of 47 patients (70 %) with severe C.
difficile colitis responded to adjunct ICV with complete
resolution without surgery. Multivariable analysis sug-
gested that failures to intra-colonic vancomycin enemas
occurred in patients who were older and frail with albu-
min < 2.5 g/dl and early surgery should be considered
for those patients. Early surgery should also be offered
to those patients who are failing maximal medical ther-
apy that include ICV enemas.
17) Fidaxomicin may be used to treat CDI, espe-
cially in the patients at higher risk for recurrence
(e.g. elderly patients with severe underlying disease
or those requiring receiving concomitant antibiotics)
(Recommendation 1 A).
Fidaxomicin orally 200 mg twice daily for 10 days may
be an alternative to vancomycin in some patients with
CDI [172, 173].
Fidaxomicin was non-inferior to vancomycin for initial
cure of CDI in two prospective trials [164, 165]. In a first
double-blind, randomized, non-inferiority trial [164] 629
adults with acute symptoms of C. difficile infection and
a positive result on a stool toxin test were enrolled and
randomly assigned to receive fidaxomicin (200 mg twice
daily) or vancomycin (125 mg four times daily) orally for
10 days. The rates of clinical cure with fidaxomicin were
non-inferior to those with vancomycin in both the
modified intention-to-treat analysis (88.2 % with fidaxo-
micin and 85.8 % with vancomycin) and the per-
protocol analysis (92.1 % and 89.8 %, respectively). Sig-
nificantly fewer patients in the fidaxomicin group than
in the vancomycin group had a recurrence of the infec-
tion, in both the modified intention-to-treat analysis
and the per-protocol analysis. In a second multi-centre,
double-blind, randomized, non-inferiority trial [165]
535 patients, 16 years or older with acute, toxin-positive
C difficile infection were randomly allocated (1:1) to re-
ceive oral fidaxomicin (200 mg every 12 h) or oral
vancomycin (125 mg every 6 h) for 10 days. Non-infer-
iority was shown for both the modified intention-to-treat
analysis (15.4 % vs. 25.3 %, P = 0.005) and the per-protocol
analysis (13.3 % vs. 24.0 %, P = 0.004). Patients receiving
concomitant antibiotics for other infections had a higher
cure rate with fidaxomicin (46 [90 · 2 %] of 51) than with
vancomycin (33 [73 · 3 %] of 45; p = 0 · 031). Fidaxomicin
may be useful for treating patients who are considered at
high risk for recurrence (elderly patients with multiple co-
morbidities who are receiving concomitant antibiotics).
However, it is important to note that there are no data
available on the efficacy of Fidaxomicin in severe life-
threatening disease.
The use of other antibiotics such as tigecycline
[174, 175] fusidic acid, teicoplanin, rifamixin [167]
and nitazoxanide [176], has been described in the lit-
erature, but they are not currently recommended for
general use.
Surgical management
Patients with fulminant colitis (FC) who progress to sys-
temic toxicity require surgical intervention.
To determine clinical predictors for the development
of fulminant colitis in patients with CDI a 10-year retro-
spective review of FC patients who underwent colectomy
was performed and compared with randomly selected
age- and sex-matched non-fulminant CDI patients at a
single institution study by Girotra in 2012 [177]. Pre-
dictive clinical and laboratory features included: old
age (>70 years), prior CDI, profound leukocytosis
(>18,000/mm3), hemodynamic instability, use of anti-
peristaltic medications, and a clinical triad of increasing
abdominal pain, distention and diarrhea.
18) Patients with severe CDI who progress to sys-
temic toxicity should undergo early surgical consult-
ation and evaluated for potential surgical intervention
(Recommendation 1 C).
Patients with severe CDI who progress to systemic
toxicity are likely to have serious comorbidities. Delaying
surgery in this group leads to increased likelihood of ad-
verse outcomes [178], although some reports show that
a short period of medical optimization can improve out-
comes before colectomy [179].
There are no reliable clinical and/or laboratory find-
ings that can predict those patients who will respond to
medical therapy and those who will subsequently need
surgery [180].
Data comparing mortality rates between surgical and
medical treatment for fulminant C. difficile colitis were
published in a recent systematic review by Stewart et al.
[181]. Five hundred and ten patients with FC were iden-
tified in six studies. Emergency colectomy for patients
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with FC provided a survival advantage compared with
continuing antibiotics. When all six studies numbering
510 patients were analysed, the pooled adjusted odds ra-
tio of mortality comparing surgery with medical therapy,
and weighted by the contribution of each study, was
0.70 (0.49–0.99) leading the authors to conclude that
emergency colectomy has a therapeutic role in treating
complicated C. difficile colitis.
Patients presenting with organ failure (acute renal fail-
ure, mental status changes, or cardiopulmonary com-
promise) also need prompt intervention.
The timing of surgical intervention is the key for sur-
vival of patients with FC [182–185].
Seder et al. [186] described 6,841 patients with CDI
and showed a decreased mortality associated with sur-
gery performed before the need for vasopressor require-
ment, especially in the patients <65 years old. Hall et al.
[184] reviewed 3,237 consecutive cases of CDI and
showed an increased mortality rate when surgical ex-
ploration was performed after intubation or the develop-
ment of respiratory failure and the use of vasopressors.
Recently a risk scoring system (RSS) for daily clinical
practice was designed by van der Wilden et al. [187].
Age greater than 70 years was assigned 2 points, white
blood cell count equal to or greater than 20,000 x 109/L
or equal to or less than 2,000 x 109/L was assigned 1
point, cardiorespiratory failure was assigned 7 points,
and diffuse abdominal tenderness on physical examin-
ation was assigned 6 points. A value of 6 points was de-
termined to be the threshold for reliably dividing low-
risk (<6) from high-risk (≥6) patients. Only patients with
cardiorespiratory failure or diffuse abdominal tenderness
were high risk.
Ferrada et al. [188] reviewed the existing literature on
the treatment of CDI and published practice manage-
ment guidelines (PMG) for the Eastern Association for
the Surgery of Trauma (EAST). The authors strongly
recommended, that adult patients with CDI undergo
early surgery before developing shock and the need for
vasopressors. Although timing remains controversial
Ferrada et al. found that it was between 3 days and 5 days
after diagnosis in patients who are worsening or not
clinically improving [188].
Many factors have been described as predictors of mor-
tality in patients who undergo emergency intervention.
Sailhamer et al. [189] reviewed the records of 4796
inpatients diagnosed with C difficile colitis. In 199
patients (4.1 %) with fulminant C difficile colitis the
in-hospital mortality rate was 34.7 %. Independent
predictors of mortality included age 70 years or older,
severe leukocytosis or leukopenia (white blood cell
count, >or = 35 000 × 109/L or <4000 × 109/L) or ban-
demia (neutrophil bands, >or = 10 %), and cardiorespira-
tory failure (intubation or vasopressors). Survival rates
were higher in patients who were cared for by surgical vs
nonsurgical departments.
The ACS-NSQIP database from 2005 to 2010 was
used by Lee et al. to study emergency open colectomies
performed for C difficile colitis in the USA [190]. The
overall mortality was 33 % (111/335). Age 80 years or
older, preoperative dialysis dependence, chronic ob-
structive pulmonary disease, and wound class III were
associated high patient mortality. Thrombocytopenia
(platelet count < 150 × 103/mm3), coagulopathy (Inter-
national Normalized Ratio > 2.0), and renal insufficiency
(blood urea nitrogen > 40 mg/dL) were also associated
with a higher mortality.
A systematic review and meta-analysis of outcomes
following emergency surgery for C. difficile colitis was
published by Banghu et al. [191]. Thirty-one studies
were included, which presented data for 1433 patients
undergoing emergency surgery for C. difficile colitis. It
concluded that the strongest predictors for postoperative
death were those relating to preoperative physiological
status: preoperative intubation, acute renal failure, mul-
tiple organ failure and shock requiring vasopressors.
19) Resection of the entire colon should be consid-
ered to treat patients with fulminant colitis (FC) (Rec-
ommendation 1 B).
20) Diverting loop ileostomy with colonic lavage may
be a useful alternative to resection of entire colon
(Recommendation 2 C).
21) Patients with FC should be treated with high
dose oral or by enema vancomycin (500 mg, 6
hourly) in combination with intravenous metronida-
zole (500 mg, 8 hourly). (Recommendation 1 C).
In the Bhangu et al. meta-analysis [191] the most com-
monly performed operation for treatment of FC was total
colectomy with end ileostomy (89 %, 1247/1401). When
total colectomy with end ileostomy was not performed, re-
operation to resect further bowel was needed in 15.9 %
(20/ 126). In the recent meta-analysis by Ferrada et al.
[188], 17 studies comparing colectomy versus other proce-
dures or no surgery as treatment for CDI were analyzed.
The authors recommended that total colectomy (vs. par-
tial colectomy or other surgery) is the procedure of choice
for patients with C. difficile colitis.
To evaluate the role of emergency colectomy in patients
with FC, and to identify subgroups of patients that may
benefit Lemontagne et al. [192] published a retrospective
observational cohort study of 165 cases of FC that required
ICU admission or prolongation of ICU stay in 2 tertiary
care hospitals of Quebec, Canada. Eighty-seven (53 %)
cases died within 30 days of ICU admission, of which
almost half (38 of 87, 44 %) died within 48 h of ICU ad-
mission. The independent predictors of 30-day mortal-
ity were leukocytosis > or = 50 × 10(9)/L, lactate > or =
5 mmol/L, age > or = 75 years, immunosuppression and
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shock requiring vasopressors. Patients who underwent an
emergency colectomy were less likely to die than those
treated medically. Colectomy was more beneficial in pa-
tients aged 65 years or more, in immunocompetent patients
and in patients with a leukocytosis > or = 20 × 109/L or lac-
tate between 2.2 and 4.9 mmol/L.
Diverting loop ileostomy with antegrade colonic lavage
may be a colon preserving alternative to total colectomy
[193, 194]. To evaluate whether a minimally invasive,
colon-preserving approach may be an alternative to sub-
total colectomy in the treatment of FC, a historical con-
trol group study was performed at the University of
Pittsburgh Medical Center or and the Veterans’ Admin-
istration Healthcare System, Pittsburgh between June
2009 and January 2011 [193]. All patients with FC were
managed by a loop ileostomy, intraoperative colonic lav-
age with warmed polyethylene glycol 3350/electrolyte
solution via the ileostomy and postoperative antegrade
instillation of vancomycin flushes via the ileostomy.
Forty-two patients were treated during this time period.
There was no significant difference in age, sex, pharma-
cologic immunosuppression, and Acute Physiology and
Chronic Health Evaluation-II scores between the studied
cohort and historical controls. The operation was ac-
complished laparoscopically in 35 patients (83 %). This
treatment strategy resulted in reduced mortality com-
pared to their historical population. Preservation of the
colon was achieved in 39 of 42 patients (93 %). Of note,
in this study vancomycin antegrade enemas were contin-
ued via the ileostomy every 6 h for 10 days after ileos-
tomy formation and this likely augmented the effect of
the defuctioning surgery.
Supportive care
22) Supportive measures, including intravenous fluid
resuscitation and electrolyte replacement, should be
provided to all patients with severe C. difficile infec-
tion (Recommendation 1 C).
Diarrhea results in significant volume depletion and
electrolyte abnormalities, and fluid and electrolyte im-
balance should be promptly corrected [119, 120].
23) Early detection of shock and aggressive manage-
ment of underlying organ dysfunction are essential for
optimum outcomes in patients with fulminant colitis
(Recommendation 1 C).
Early detection and prompt aggressive treatment of
the underlying organ dysfunction is an essential compo-
nent of improving outcome of critical ill patients [120].
Severe CDI may present with a fulminant course and
may be associated with great morbidity and high mortal-
ity. Physiologic support including close invasive moni-
toring in an intensive care unit setting and aggressive
resuscitation are often necessary in fulminant colitis.
Recurrent C. difficile infection (RCDI)
Recurrence is diagnosed when CDI recurs <8 weeks after
the onset of a previous episode, provided the symptoms
from the previous episode resolved after completion of
initial treatment and other causes have been excluded.
Symptomatic recurrent C difficile infection (RCDI) oc-
curs in approximately 20 % of patients and is challenging
to treat [195]. Patients with recurrence of CDI should
therefore be treated by clinicians who have experience in
treating the infection.
24) Agents that may be used to treat the first recur-
rence of CDI include metronidazole, for non-severe
RCDI, and vancomycin for severe RCDI. (Recommen-
dation 1 B).
25) Fidaxomicin may be used as an alternative agent
(Recommendation 1 B).
A systematic review on the treatment of RCDI was re-
cently published [196]. Metronidazole and vancomycin
have a good evidence base for use in RCDI but heterogen-
eity in treatment duration and treatment doses between
the studies precluded robust conclusions. Fidaxomicin
may also have a role in the treatment of first recurrence.
Fidaxomicine was superior to vancomycin in terms of re-
currences, with significantly less recurrence at 28 days.
This was confirmed in some subgroup analysis [197].
26) In subsequent recurrence of CDI (2nd or later)
oral vancomycin or fidaxomicin is recommended
(Recommendation 1 B).
Vancomycin and fidaxomicin are equally effective in re-
solving CDI symptoms but fidaxomicin has been shown
to be associated with a lower likelihood of CDI recurrence
after a first recurrence [164, 165, 197]. However, there are
no prospective randomized controlled trials investigating
the efficacy of fidaxomicin in patients with multiple recur-
rences of CDI. Vancomycin is often administered using a
prolonged tapered and/or pulsed regimen which may be
more effective than a standard 10 to 14 day course al-
though no RCTs have been reported [198].
Probiotics
27) Probiotics may be considered as an adjunctive
treatment to antibiotics for immunocompetent pa-
tients with RCDI (Recommendation 2 B).
Little evidence exists to support the use of probiotics
in the first episode of CDI [116]. Two randomized con-
trolled trials showed some effectiveness for Saccharomy-
ces boulardii CNCM I-745 in recurrent CDI. The first
demonstrated a lower relapse rate compared with a pla-
cebo control group (35 vs 65 % in the placebo group)
[199] and the second found that the combination of S.
boulardii (1 g/d) with high dose vancomycin (2 g/d) was
more effective than high dose vancomycin and placebo
(17 vs 50 % recurrence rate) [200]. Other studies with
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Lactobacillus strains (L. rhamnosus GG or L. plantarum
299v) were stopped prematurely due to enrollment
problems [201]. Probiotics should not be administered
to patients at risk of bacteraemia or fungaemia [116].
There is limited evidence to support the use of probio-
tics for the primary prevention of CDI from developing.
A meta-analysis of 11 studies was in published 2012
[202]. Two studies showed significantly lower rates of
CDI among the probiotic recipients. A meta-analysis of
three studies that used the probiotic combination Lacto-
bacillus acidophilus CL1285 and Lactobacillus casei
LBC80R and a combined analysis of those studies with
four studies that used Saccharomyces boulardii, showed
lower CDI rates in recipients of probiotics compared
with recipients of placebo (risk ratio = 0.39; 95 % confi-
dence interval 0.19–0.79. However, given the potential
risk of bloodstream infection with these organisms fur-
ther studies are warrented before their use can be rec-
ommended routinely.
Faecal microbiota transplantation
28) Intestinal or faecal microbiota transplantation
(IMT or FMT) may be an effective option for the
treatment of RCDI (Recommendation 1 B).
Intestinal or faecal microbiota transplantation (IMT or
FMT) has been considered as an alternative therapy to
treat RCDI [203–208]. It involves infusing intestinal mi-
croorganisms (in a suspension of healthy donor stool)
into the intestine of patients to restore the intestinal
microbiota.
The rationale of FMT is that disruption of the normal
balance of colonic flora allows C. difficile strains to grow
and produce CDI. By reintroducing normal flora via
donor faeces, the imbalance may be corrected, and nor-
mal bowel function re-established [203].
FMT has not been widely adopted as a therapeutic
tool probably due to concerns regarding safety and ac-
ceptability [204].
A systematic literature review of IMT treatment for
RCDI and pseudomembranous colitis was published in
2011 by Gough et al. [205]. In 317 patients treated
across 27 case series and reports, IMT was highly effect-
ive, showing disease resolution in 92 % of cases. In those
studies, 35 % of patients received IMT via enema, with a
response rate of 95; 23 % patients received IMT via
naso-jejunal tube by gastroscope, with a response rate of
76; and 19 % via colonoscopy, with a response rate of
89 %. Effectiveness varied by route of instillation, rela-
tionship to stool donor, volume of IMT given, and treat-
ment before infusion.
Recently a systematic review was published by
Cammarota et al. [206]. Twenty full-text case series, 15
case reports, and 1 randomized controlled study were in-
cluded for the final analysis. Almost all patients treated
with donors’ fecal infusion experienced recurrent episodes
of CD-associated diarrhea despite standard antibiotic
treatment. Of a total of 536 patients treated, 467 (87 %)
experienced resolution of diarrhea. Diarrhea resolution
rates varied according to the site of infusion: 81 % in the
stomach; 86 % in the duodenum/jejunum; 93 % in the
cecum/ascending colon; and 84 % in the distal colon. No
severe adverse events were reported with the procedure.
In a recently published randomized clinical trial by
van Nood et al. [208] patients with RCDI were rando-
mised to three groups; 1) vancomycin regime only; 2)
vancomycin with duodenal infused FMT and 3) vanco-
mycin and bowel lavage. In the FMT treated group an
81% reduction in diarrhoea was observed. The FMT
group were observed to have normalization of their in-
testinal bacterial composition which was similar to that
of the donor. Although, this trial has shown exciting re-
sults, these need to be interpreted with caution as the
trial included only small number of patients, was not
blinded, and was aborted early due to profound differ-
ences in the groups. It has also been criticised for poten-
tially having several potential biases.
FMT may be administered via enemas or as a slurry
given via a nasogastric tube. In the fall of 2014, Youngster
et al. [209] reported their experience on utilizing frozen
FMT capsules in 20 patients who had RCDI. Fourteen pa-
tients (70 %) had resolution of diarrhea after the first treat-
ment, and an additional 4 patients responded after a
second treatment, for a clinical resolution rate of 90 %.
29) FMT may be effective in immunocompromised
patients and patients who have had solid organ
transplants (Recommendation 2 B).
Patients who are immunocompromised are at increased
risk of CDI. During the last two years the first data on
FMT in immunocompromised patients began to appear in
the medical literature [210].
A multicenter retrospective series on the use of FMT in
immunocompromised (IC) patients with CDI that was re-
current, refractory, or severe was published in 2014 [211].
Reasons for IC included: HIV/AIDS (3), solid organ trans-
plant (19), oncologic condition (7), immunosuppressive
therapy for inflammatory bowel disease (IBD; 36), and
other medical conditions/medications (15).
This series demonstrated the effective use of FMT for
CDI in IC patients with few serious adverse events or re-
lated adverse events.
Intravenous immunoglobulin (IVIG)
30) IVIG should only be used as adjunct therapy in
patients with multiple recurrent or fulminant CDI
until results from large, randomized controlled trials
are available (Recommendation 2 C).
Sartelli et al. World Journal of Emergency Surgery  (2015) 10:38 Page 15 of 23
IVIG treatment has been proposed based on the evi-
dence that the level of immune response to C. difficile
colonization is a major determinant of magnitude and
duration of clinical manifestations. Passive immunization
with IVIG has been reported to be successful in several
small series. A review by Abourgergi [212] of fifteen small,
mostly retrospective and non-randomized studies docu-
mented success with IVIG in the treatment of protracted,
recurrent, or severe CDI. The authors concluded IVIG
should only be used as adjunct therapy until results from
large, randomized controlled trials are available.
Monoclonal antibodies
31) Infusion with monoclonal antibodies may be of
use to prevent recurrences of CDI, particularly in
patients with CDI due to the 027 epidemic strain
(Recommendation 2 C).
In a phase II clinical trial [213], the use of monoclonal
antibodies to toxins A and B as an adjunct to antibiotics
was shown to decrease recurrence rates in patients with
CDI compared with placebo (7 vs. 25 % respectively;
95 % confidence interval, 7 to 29; P < 0.001). The recur-
rence rates among patients with the epidemic BI/NAP1/
027 strain were 8 % for the antibody group compared
with 32 % for placebo (P = 0.06); among patients with
more than one previous episode of CDI, recurrence rates
were 7 and 38 %, respectively (P = 0.006). The authors
concluded that the addition of monoclonal antibodies
against C. difficile toxins to antibiotic agents significantly
reduced the recurrence of C. difficile infection. The find-
ings of this study require confirmation before firm rec-
ommendations can be made.
Enteral nutrition in CDI
32) Tube feeding patients should be clinically
assessed due to their risk for developing CDI (Rec-
ommendation 2 C).
It is widely accepted that enteral nutrition (EN) main-
tains gut mucosal integrity which leads to decreased intes-
tinal permeability, decreased infections, and an improved
immunological status. EN during episodes of diarrhea
may be well tolerated and may improve enterocyte healing
and maintenance of enzyme activity [214, 215]. EN, how-
ever, has also been associated with increased risk of CDI
[216]. Bliss, et al. evaluated 76 tube-fed and non tube-fed
hospital patients for the development of CDI [217]. Pa-
tients were controlled for age, severity of illness and dur-
ation of hospitalization. Patients who were tube-fed were
statistically more likely to develop C difficile associated
diarrhea (20 versus 8 % p = 0.03). One of the reasons may
be prolonged use of elemental diets. It is known that crit-
ically ill patients tolerate feeding well if the feed is given in
elemental form and delivered beyond the stomach into
the jejunum because it is totally absorbed within the upper
small intestine [218]. Elemental diets are completely
absorbed within the small intestine and therefore deprive
the colonic microbiota of their source of nutrition, such as
dietary fiber, fructose oligosaccharides, and resistant starch
[219]. The resultant suppression of colonic fermentation
may therefore lead to the disruption of the normal gut
flora and the creation of a “permissive” environment for
C. difficile colonization and subsequent infection. In
feeding tube patients the conversion of elemental diet
feeding to a diet containing adequate indigestible carbo-
hydrate after the first week of critical illness may, in the-
ory, be useful.
Recently, Puri et al. [220] reported that daily concomi-
tant treatment with 4 g cholestyramine in patients receiv-
ing long-term intravenous ceftriaxone (2 to 4 g
ceftriaxone daily, for an average of >10 weeks) was associ-
ated with CDI in only three out of 46 patients (6.5 %)
compared with 23.1 % of those receiving ceftriaxone alone
[221]. Cholestyramine (or colestyramine) is a hydrophilic,
water insoluble, non-digestible basic anion-exchange resin
which can bind luminal TcdA and TcdB.
Studies have also investigated the possible value of ex-
ogenous Phosphatidylcholene (PC) administration for
reinforcement of the mucus layer [222, 223]. Mucus or
“exogenous” mucus in the form of PC may have a syner-
gistic role with secretory IgA as a barrier against C. diffi-
cile toxin A though additional studies are needed to
demonstrate its clinical benefit before recommendations
can be made [222, 223].
Anti-motility agents
33) The use of anti-peristaltic agents for the treatment
of CDI should be discouraged. If anti-peristaltic, if used
in isolation agents, are used to control persistent symp-
toms in patients with CDI they must always be accom-
panied by medical therapy (Recommendation 2 C).
A review of the literature regarding anti-motility treat-
ment of CDI found 55 patients with CDI who were ex-
posed to anti-motility agents [224].
Nine patients (16 %) died, and 27 patients (49 %) had
unknown outcomes. Seventeen patients (31 %) with
CDI developed colonic dilation; 5 of these patients with
severe CDI died. However, all patients who experienced
complications or died were given anti-motility agents
alone initially, without an appropriate antibiotic and 23
patients who received metronidazole or vancomycin co-
administered with the anti-motility agent experienced
no complications. Further study of the role of anti-
motility agents in providing symptomatic relief and re-
ducing environmental contamination with infectious
stool may be warranted though, until there is clear evi-
dence of benefit, their use in patients with CDI should
be avoided [116].
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Prevention
34) Proper antimicrobial stewardship in selecting an
appropriate antibiotic and optimizing its dose and
duration to cure an infection may prevent the emer-
gence of C. difficile (Recommendation 1 B).
Despite vigorous infection control measures until
recently, CDI was causing an increasing problem in
healthcare facilities worldwide. As CDI is thought to
follow disruption to the normal bacterial flora of the
colon occurring as a consequence of antibiotic use
[225], it is logical that antibiotic stewardship pro-
grams may be useful in preventing CDI [226]. Good
antimicrobial stewardship involves ensuring appropri-
ate antibiotic choice and optimizing antibiotic dose
and duration to cure an infection while minimizing
toxicity and conditions conducive to CDI. Recently, a
systematic review [227] of interventions to improve
antibiotic prescribing practices for hospital inpatients
suggested that reducing excessive antibiotic prescrib-
ing can prevent hospital-acquired infections and that
interventions to increase effective prescribing improve
clinical outcome. It would appear that cephalosporin
and quinolone antibiotics may be particularly high
risk, in this context [116, 228].
35) Patients with suspected or proven CDI should
be placed in contact (enteric) precautions (Recom-
mendation 1 B).
Prompt identification of patients with symptomatic
CDI is essential so that appropriate isolation precautions
can be put into effect.
This is particularly important in reducing environmen-
tal contamination as spores can survive for months in
the environment [229], despite regular use of environ-
mental cleaning agents.
Contact (enteric) precautions patients with CDI should
be maintained until the resolution of diarrhea, which is
demonstrated by passage of formed stool for at least
48 h. Patients with known or suspected CDI should
ideally be placed in a private room [116, 230] with en-
suite hand washing and toilet facilities. If a private room
is not available known CDI patients may be cohort
nursed in the same area [231] though the theoretical risk
of transfection with different strains exists.
This is supported by a retrospective cohort of 2859 pa-
tients by Chang et al. [232]. Patients who were roommates
or neighbors of a patient with CDI were at risk of nosoco-
mial acquisition of CDI (RR, 3.94; 95 % CI, 1.27–12.24).
36) Hand hygiene with soap and water is a corner-
stone of the prevention of C. difficile. Hand hygiene,
contact precautions and good cleaning and disinfec-
tion of the environment and patient care equipment,
should be used by all health-care workers contacting
any patient with known or suspected CDI (Recom-
mendation 1 B).
Hand hygiene with soap and water and the use of con-
tact precautions along with good cleaning and disinfec-
tion of the environment and patient equipment, should
be used by all health-care workers contacting any patient
with known or suspected CDI. Hand hygiene is a corner-
stone of prevention of nosocomial infections, including
C. difficile. Alcohol-based hand sanitizers are highly ef-
fective against non–spore-forming organisms, but they
may not kill C. difficile spores or remove C. difficile from
the hands [233, 234].
The most effective way to remove them from hands is
through hand washing with soap and water.
For environmental cleaning, hypochlorite disinfection
such as sodium hypochlorite solutions are suggested for
regular use in patient areas where C. difficile transmis-
sion is ongoing [231].
Though disposable glove use during care of a patient
with CDI may be effective in preventing the transmis-
sion of C. difficile [230], these must be removed at the
point of use and hands thoroughly decontaminated
afterwards through soap and water hand washing.
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